Company intelligence / Profile preview

Teclison

Princeton, New Jersey, United Stateszoominfo.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Teclison is conducting Phase 2 clinical trials for TATE plus anti-PD-1 in the USA and Taiwan. Several advanced cancer patients have achieved long-term survival in these trials. Some advanced cancer patients showed dramatic response after TATE plus anti-PD-1 treatment even after failing immunotherapy before enrollment, demonstrating synergy with immunotherapy. The company plans to report robust response for advanced HCC patients who were refractory to immunotherapy at an upcoming ASCO annual meeting.

Therapeutic areas: Oncology
Modalities: Small molecule drugsChemical drugs
Industry: Biotech

Drug pipeline

4 assets

tirapazamine

3 more assets in the full pipeline.

Request access →

Partnerships

Merck & Co. (Clinical Trial Collaboration and Supply Agreement)

Beyond the preview

Go deeper on Teclison.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Teclison.

Explore the full profile